Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
07:00am, Monday, 25'th Mar 2024
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop
Newly granted patent aligns with Company's focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 Newly granted patent aligns with Company's focus on exp
BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript
11:00am, Tuesday, 12'th Mar 2024
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q4 2023 Earnings Conference Call March 12, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Vince O'Neill - Chief of Product and Dev
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
07:00am, Tuesday, 12'th Mar 2024
Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY pro
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
02:52pm, Thursday, 07'th Mar 2024
There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an or
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
07:00am, Friday, 01'st Mar 2024
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neu
BioXcel Therapeutics Announces Termination of Proposed Public Offering
09:00am, Tuesday, 13'th Feb 2024
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
09:05am, Friday, 09'th Feb 2024
BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Friday after the commercial-stage biopharmaceutical company announced a proposed underwritten public offering for its shares. This pu
BioXcel Therapeutics Announces Proposed Public Offering
04:01pm, Thursday, 08'th Feb 2024
NEW HAVEN, Conn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop t
Human proof of concept portion of the trial expected to begin in H1 2024; led by Georgetown Lombardi Comprehensive Cancer Center
Aligns with Company's strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer's patients
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
07:00am, Tuesday, 12'th Dec 2023
Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer's disease and BXCL502 as a potential treatment for chronic
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
07:00am, Monday, 11'th Dec 2023
Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer Rajiv Patni, M.D.
7 Penny Stocks With Low Floats and High Short Interest
06:40am, Friday, 24'th Nov 2023
There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short
